Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

GSK 256066

Known as: GSK-256066, GSK256066 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2016
Review
2016
Extensive research into the therapeutics of asthma has yielded numerous effective interventions over the past few decades… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • table 1
2015
2015
This study examined the pharmacologic characterization of CHF6001 [(S)-3,5-dichloro-4-(2-(3-(cyclopropylmethoxy)-4… Expand
  • table 1
  • table 2
  • table 3
2015
2015
Cyclic nucleotide phosphodiesterases (PDEs) have been identified as important enzyme targets for drug development in both humans… Expand
2013
2013
BACKGROUND Inhibition of phosphodiesterase 4 (PDE4) represents an approach to anti-inflammatory therapy in chronic obstructive… Expand
Highly Cited
2011
Highly Cited
2011
Oral phosphodiesterase (PDE) 4 inhibitors such as roflumilast have established the potential of PDE4 inhibition for the treatment… Expand
  • figure 1
  • table 1
  • table 2
  • figure 2
  • figure 3
2011
2011
Oral phosphodiesterase (PDE) 4 inhibitors have demonstrated clinical efficacy in chronic obstructive pulmonary disease and asthma… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
Review
2011
Review
2011
Since more than two decades anti-inflammatory effects of inhibitors of phosphodiesterase-4 have been described in numerous… Expand
  • figure 1
  • figure 2
  • table 1
  • figure 3
  • figure 4
Highly Cited
2010
Highly Cited
2010
GSK256066 is a selective phosphodiesterase 4 inhibitor that can be given by inhalation, minimising the potential for side effects… Expand
  • table 1
  • figure 1
  • figure 2
  • figure 3
  • table 2
2009
2009
Crystallography driven optimisation of a lead derived from similarity searching of the GSK compound collection resulted in the… Expand
  • table 1
  • figure 1
  • table 3
  • table 2
  • table 4